Company Overview

Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for rare and severe diseases, particularly in immunology and hematology. The company operates within the biopharmaceutical and rare disease sectors, with a strategy centered on antibody-based and immune-modulating therapies designed to address conditions with high unmet medical need and limited existing treatment options.

Rallybio’s primary value driver is its lead clinical program, RLYB212, a monoclonal antibody candidate intended for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare and potentially life-threatening condition. The company was founded in 2018 and has evolved through in-licensing and internal development of targeted biologics, advancing from preclinical research to clinical-stage development. Rallybio became a publicly traded company in 2021 following its initial public offering.

Business Operations

Rallybio’s operations are focused on research and development, with no approved commercial products as of the most recent public disclosures. Its core business activities include discovery, preclinical development, clinical trials, and regulatory planning for biologic therapies. The company’s pipeline is concentrated in immune-mediated rare diseases, with RLYB212 representing the most advanced program and primary source of potential future revenue.

The company operates primarily in the United States and relies on a combination of internal scientific expertise and external partners, including contract research organizations and manufacturing partners, to conduct clinical trials and produce investigational drug material. Rallybio maintains full or primary development and commercialization rights to its key programs, and no material joint ventures generating revenue have been publicly disclosed. Data on additional late-stage partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Rallybio’s strategic direction emphasizes advancing its lead clinical asset through late-stage development while selectively expanding its pipeline through disciplined investment in additional rare disease programs. The company has publicly stated a focus on diseases where prevention or early intervention can significantly alter outcomes, positioning itself within niche markets that may support orphan drug designation and streamlined regulatory pathways.

The company has made targeted investments in early-stage programs addressing immune-mediated and complement-driven diseases. In addition to RLYB212, Rallybio has disclosed preclinical and earlier-stage assets intended to diversify its pipeline, though none have reached the same level of clinical validation. No transformative acquisitions have been confirmed in public filings, and information on material equity investments in external companies is inconclusive based on available public sources.

Geographic Footprint

Rallybio is headquartered in the United States, with its principal executive offices in Massachusetts, a major hub for biotechnology research and development. Its operational footprint is primarily domestic, reflecting its current stage as a clinical-stage company without commercial sales infrastructure.

While Rallybio does not maintain significant owned international facilities, its clinical development activities have involved or are expected to involve trial sites outside the United States, including in Europe, depending on study design and regulatory requirements. The company’s international presence is therefore primarily clinical and regulatory rather than operational or commercial.

Leadership & Governance

Rallybio was founded by executives with prior experience in large biopharmaceutical companies and rare disease drug development. The leadership team emphasizes a science-driven and patient-focused philosophy, prioritizing rigorous clinical validation and regulatory alignment in rare indications.

Key members of the executive leadership team include:

• Stephen Uden – President & Chief Executive Officer
• Jonas Mårtensson – Chief Financial Officer
• Amit Munshi – Executive Chairman
• Karen L. Hong – Chief Medical Officer

The company is governed by a board of directors with experience in biotechnology, capital markets, and drug development. Leadership and governance practices are aligned with U.S. public company standards as disclosed in SEC filings, including annual and quarterly reports.